)
Visual
test
Marinomed Biotech
Marinomed Biotech (MARI) investor relations material
Marinomed Biotech H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary17 Sep, 2025
Executive summary
Achieved sustainable profitability after restructuring and sale of Carragelose business, with proceeds bridging to Marinosolv platform revenues.
Entered a partnership for Budesolv in Switzerland, securing upfront, milestone payments, and royalties.
Focus shifted to Marinosolv technology and Solv4U services, with new licensing and partnership opportunities.
Sale of Carragelose business to Unither Pharmaceuticals completed, with initial €5M payment received and up to €20M in total possible.
Announced convertible bond issue and capital increase to strengthen liquidity.
Financial highlights
Revenue for H1 2025: €7.2M (H1 2024: €2.4M), mainly from Carragelose sale upfront payment.
Other operating income: €19.3M (H1 2024: €53K), driven by €18.9M restructuring gain.
Operating profit: €21.0M (H1 2024: -€3.2M); Net profit: €20.7M (H1 2024: -€3.8M).
Cash and cash equivalents at period end: €1.5M (H1 2024: €0.9M).
Negative equity reduced to -€5.4M (2024: -€26.2M).
Outlook and guidance
Focus on licensing Budesolv in additional territories and advancing Tacrosolv partnerships.
Anticipates profitability from 2025 onwards, leveraging Marinosolv and Solv4U platforms.
Convertible bond and capital increase to support liquidity and project advancement.
Impact of new financing on liquidity & going concern?
Progress on Marinosolv lead product partnerships?
Assess Carragelose earn-out payment risks.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebSCW
Q2 2025 revenue up 120% y/y, driven by record Asian contract and backlog growth. - 6 FebSCWRevenue up 89% y/y, record backlog, and new strategy for European optical payload leadership.
- 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, driven by major space contracts.
- 6 FebSCWSpace segment drives 29% revenue growth, strong backlog and contracts support 2025 outlook.
- 6 FebSCW73% revenue growth, record backlog, and major space contracts drive expansion and investment.
- 6 FebPENG
All proposals passed, with no questions raised and results to be filed on Form 8-K. - 6 FebSCWQ1 2025 revenue surged 97% year-over-year, with strong backlog and new contracts secured.
- 6 FebCRI
Revenue up sharply, net loss reduced, and strong cash inflow from share issue and contracts. - 6 FebNVDA
AI-driven virtual twins and accelerated computing are revolutionizing design and manufacturing. - 6 FebSPKSJF
Record income, strong growth, and robust capital position despite lower interest income.
Next Marinomed Biotech earnings date
H2 202515 Apr, 2026
Marinomed Biotech
Next Marinomed Biotech earnings date
H2 202515 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Marinomed Biotech AG is an Austrian biotechnology company specializing in antiviral and immunology products. The company develops therapies based on proprietary technology platforms for treating respiratory and ocular diseases. It focuses on both prescription and over-the-counter formulations with applications in global healthcare markets. The company is headquartered in Korneuburg, Austria, and its shares are listed on the VSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage